Elsevier

Joint Bone Spine

Volume 74, Issue 5, October 2007, Pages 500-503
Joint Bone Spine

Case report
Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis

https://doi.org/10.1016/j.jbspin.2006.12.004Get rights and content

Abstract

Thalidomide is an immunomodulating agent which reverses many of the cytokine disturbances seen in systemic onset juvenile idiopathic arthritis (SoJIA) with inadequate response to other treatments. We report 3 cases of recalcitrant SoJIA which improved dramatically after treatment with thalidomide.

Patients

Three children aged 9, 8, and 6 years diagnosed with SoJIA treated with conventional therapy including NSAIDs, corticosteroids, methotrexate and etanercept failed to respond fully and their condition worsened. Thalidomide was begun based on two previous reports showing its efficacy in recalcitrant SoJIA.

Results

Thalidomide produced successful remission of the disease in all 3 patients according to the preliminary criteria for inactive disease and clinical remission of JIA.

Conclusion

Thalidomide may be a viable, alternative corticoid-sparing therapy in patients with recalcitrant, multidrug-resistant SoJIA.

Introduction

Systemic onset juvenile idiopathic arthritis (SoJIA) is a severe, debilitating inflammatory condition characterized by fever, rash and arthritis with many laboratory abnormalities including leukocytosis, thromobocytosis, anaemia, dramatically elevated erythrocyte sedimentation rate (ESR), elevated C-reactive protein (CRP), and elevated ferritin with a specific pattern of cytokine abnormalities [1]. The current definition of Juvenile idiopathic arthritis (JIA) is arthritis of unknown aetiology that begins before the 16th birthday and persists for at least 6 weeks [2]. It has recently been suggested that SoJIA is a distinct entity from JIA, and that the aetiology, pathogenesis, and therapy of children with SoJIA should be considered separately from those with other forms of JIA [3]. Approximately one-third of children with SoJIA are dependent on corticosteroids to control the systemic manifestations of the disease and are at high-risk for steroid-associated morbidity. The permanent physiologic and psychological sequelae associated with long-term steroid use are well documented and should be avoided [1], [4]. Current non-steroidal therapies available for the treatment of SoJIA alone or in combination include: anakina, autologous stem cell transplantation, azathioprine, cyclophosphamide, cyclosporine, etanercept, infliximab, intravenous gamma-globulin, methotrexate, sulfasalazine, and tocilizumab [3]. None has proven to be consistently successful. Thalidomide is a unique anti-inflammatory agent that reduces the production of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) and suppresses angiogenesis and cell adhesion molecule expression [5], [6].

Section snippets

Patient 1

A 9-year-old girl who fulfilled the criteria for SoJIA was seen in our center. She was started on prednisone 0.2 mg/kg/day, methotrexate 10 mg/m2/week p.o. and non-steroidal anti-inflammatory drugs (NSAID) (aspirin 80 mg/kg/day). The dose of methotrexate was raised to 15 mg/m2/week but marked active synovitis and constitutional symptoms persisted. It was decided to initiate etanercept at a dose of 0.4 mg/kg SC twice weekly due to the inadequate therapeutic response to conventional treatment. Before

Discussion

It is known that, in children with active SoJIA, TNF-α is significantly overproduced while interferon gamma levels are markedly decreased [8], [9]. Polymorphisms in the 5′-flanking promoter/enhancer region of TNF-α in patients with SoJIA have been reported compared with other types of JIA and healthy controls [10]. Levels of interleukin-6, interleukin-8 and monocyte chemo-attractant protein-1 are also altered. Interleukin-6 levels increase in SoJIA patients with active disease and decrease with

Acknowledgment

The authors thank David Buss for his editorial assistance.

References (18)

There are more references available in the full text version of this article.

Cited by (34)

  • Gastrointestinal inflammation plays a critical role in chemotherapy-induced nausea and vomiting

    2022, European Journal of Pharmacology
    Citation Excerpt :

    Thalidomide also plays a vital role in the modulation of various pro-inflammatory cytokines (Rowland et al., 1998; Franks et al., 2004), especially TNF-α (Wnendt et al., 1996). Indeed, later studies revealed that thalidomide exerts anti-inflammatory effects in various inflammatory diseases (García-Carrasco et al., 2007; Rodrigues et al., 2007), including GI inflammation (Bariol et al., 2002; Mazzon et al., 2005; Prakash et al., 2008). To summarize, the anti-inflammatory effects of antiemetic drugs in the GI tract is critical in preventing CINV, emphasizing the pathogenic role of GI inflammation in CINV.

  • Natural products-based polypharmacological modulation of the peripheral immune system for the treatment of neuropsychiatric disorders

    2020, Pharmacology and Therapeutics
    Citation Excerpt :

    Studies have shown that thalidomide is potentially effective in relieving joint pain in RA patients (Gutierrez-Rodriguez, Starusta-Bacal, & Gutierrez-Montes, 1989), demonstrating a refractoriness phenotype partially mediated by TNF-α (Dredge, Marriott, & Dalgleish, 2002; J. J. Wu, Huang, Pang, Hsu, & Tyring, 2005). In a case study, thalidomide has been shown to successfully ameliorate inflammatory conditions in patients with juvenile RA, probably by reducing the production of IL-6 (Garcia-Carrasco, Fuentes-Alexandro, Escarcega, Rojas-Rodriguez, & Escobar, 2007). In a transgenic model of PD overexpressing α-syn under the murine Thy-1 promoter, thalidomide restored striatal dopamine fibre loss and reduced the production of IL-1β, IL-6, IFN-γ and TNF-α (Martinez & Peplow, 2018).

  • Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches

    2015, Clinical Immunology
    Citation Excerpt :

    The mechanism of action, however, remained elusive and published evidence for the use of thalidomide in sJIA is sparse and limited to case reports and small series. Given the general lack of controlled studies and the availability of modern target-directed treatment options, the use of this agent appears obsolete and cannot generally be recommended [66]. As a very last resort in desperate situations, autologous hematopoietic stem-cell transplantation may be considered.

  • Review of thalidomide use in the pediatric population

    2015, Journal of the American Academy of Dermatology
  • Systemic Juvenile Idiopathic Arthritis

    2015, Textbook of Pediatric Rheumatology
  • Pharmacology and Drug Therapy: Nonbiologic Therapies

    2015, Textbook of Pediatric Rheumatology
View all citing articles on Scopus
View full text